Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
19.3M
-
Number of holders
-
97
-
Total 13F shares, excl. options
-
122M
-
Shares change
-
+4.46M
-
Total reported value, excl. options
-
$389M
-
Value change
-
+$15.2M
-
Put/Call ratio
-
11.33
-
Number of buys
-
46
-
Number of sells
-
-49
-
Price
-
$3.18
Significant Holders of Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 per share (LYEL) as of Q2 2023
115 filings reported holding LYEL - Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 per share as of Q2 2023.
Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 per share (LYEL) has 97 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 122M shares
.
Largest 10 shareholders include MWG Management Ltd. (20.2M shares), VANGUARD GROUP INC (16.9M shares), Orland Properties Ltd (15.1M shares), BlackRock Inc. (13.1M shares), Foresite Capital Management IV, LLC (9.7M shares), PRICE T ROWE ASSOCIATES INC /MD/ (8.16M shares), STATE STREET CORP (6.17M shares), Alphabet Inc. (5.87M shares), GEODE CAPITAL MANAGEMENT, LLC (3.38M shares), and MIC Capital Management UK LLP (3.06M shares).
This table shows the top 97 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.